The company's focus is on bringing technologies to market that help with the treatment, prevention, or cure of Alzheimer's, with a pipeline consisting of two novel therapeutic drug candidates - AL001, which delivers lithium via a therapeutic combination of lithium, proline, and salicylate, and AL002, which uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the patient's immunological system. Alzamend Neuro was founded in 2016 and is headquartered in Newport Beach, CA, USA, with a mission to develop and market safe and effective treatments for neurodegenerative diseases and psychiatric disorders, including Alzheimer's.